Accessibility: Skip TopNav
PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine
Versamune® T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine
Format
JPEG
Source
PDS Biotechnology Corporation
Downloads
Original
Large
Medium
Small